1.24
price up icon2.48%   0.03
after-market アフターアワーズ: 1.21 -0.03 -2.42%
loading
前日終値:
$1.21
開ける:
$1.22
24時間の取引高:
694.11K
Relative Volume:
1.38
時価総額:
$76.78M
収益:
$248.00K
当期純損益:
$-113.22M
株価収益率:
-0.6733
EPS:
-1.8416
ネットキャッシュフロー:
$-98.81M
1週間 パフォーマンス:
+7.83%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-21.52%
1年 パフォーマンス:
-3.88%
1日の値動き範囲:
Value
$1.21
$1.26
1週間の範囲:
Value
$1.1538
$1.26
52週間の値動き範囲:
Value
$1.09
$1.95

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
名前
Pliant Therapeutics Inc
Name
セクター
Healthcare (1111)
Name
電話
650-481-6770
Name
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
職員
49
Name
Twitter
Name
次回の収益日
2026-05-14
Name
最新のSEC提出書
Name
PLRX's Discussions on Twitter

Compare PLRX vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
PLRX icon
PLRX
Pliant Therapeutics Inc
1.24 74.92M 248.00K -113.22M -98.81M -1.8416
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
435.93 110.28B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
634.62 66.98B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
808.43 50.15B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
295.50 39.71B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
154.89 32.22B 742.00K -1.37B -1.07B -7.0731

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-10 ダウングレード JP Morgan Neutral → Underweight
2025-03-04 再開されました Cantor Fitzgerald Neutral
2025-03-04 ダウングレード Needham Buy → Hold
2025-03-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-03-03 ダウングレード Stifel Buy → Hold
2025-02-10 ダウングレード Canaccord Genuity Buy → Hold
2025-02-10 ダウングレード Citigroup Buy → Neutral
2025-02-10 ダウングレード H.C. Wainwright Buy → Neutral
2025-02-10 ダウングレード JP Morgan Overweight → Neutral
2025-02-10 ダウングレード Oppenheimer Outperform → Perform
2025-02-10 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-02-10 ダウングレード Wells Fargo Overweight → Equal Weight
2024-09-09 再開されました Leerink Partners Outperform
2023-12-08 開始されました Wells Fargo Overweight
2023-05-18 開始されました Canaccord Genuity Buy
2023-04-13 開始されました Robert W. Baird Outperform
2022-12-14 開始されました Stifel Buy
2022-12-07 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Buy
2022-07-20 開始されました SVB Leerink Outperform
2022-05-25 開始されました Cantor Fitzgerald Overweight
2021-12-10 開始されました Oppenheimer Outperform
2021-11-24 開始されました RBC Capital Mkts Outperform
2021-11-03 開始されました H.C. Wainwright Buy
2021-04-20 開始されました BTIG Research Buy
2021-04-05 開始されました Citigroup Buy
2020-06-29 開始されました Citigroup Buy
2020-06-29 開始されました Cowen Outperform
2020-06-29 開始されました Needham Buy
2020-06-29 開始されました Piper Sandler Overweight
すべてを表示

Pliant Therapeutics Inc (PLRX) 最新ニュース

pulisher
May 22, 2026

Pliant Therapeutics to present Phase 1b trial data of PLN-101095 at ASCO 2026. - Pluang

May 22, 2026
pulisher
May 21, 2026

Pliant Therapeutics (PLRX) Bounces 2.5% as Biotech Tests Key ResistanceStock Idea Network - newser.com

May 21, 2026
pulisher
May 21, 2026

Global oncology researchers to review FORTIFY data as Pliant Therapeutics joins ASCO meeting - Traders Union

May 21, 2026
pulisher
May 21, 2026

Pliant Therapeutics (PLRX) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.32Crowd Entry Signals - newser.com

May 21, 2026
pulisher
May 21, 2026

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical ... - Caledonian Record

May 21, 2026
pulisher
May 21, 2026

Pliant Therapeutics Announces Upcoming Presentation at the - GlobeNewswire

May 21, 2026
pulisher
May 21, 2026

Phase 1 cancer trial pairs oral integrin inhibitor with pembrolizumab - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Pliant Therapeutics (PLRX) Stock: Consolidating at $1.20 — Next Move Ahead 2026-05-21Equity Put Call - Newser

May 21, 2026
pulisher
May 20, 2026

Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 20, 2026
pulisher
May 15, 2026

Australian biotech advancing pulmonary program adds Pliant CEO as chair - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board - Quantisnow

May 15, 2026
pulisher
May 14, 2026

TradingKey - TradingKey

May 14, 2026
pulisher
May 13, 2026

Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail

May 13, 2026
pulisher
May 12, 2026

Number of shareholders of Pliant Therapeutics, Inc. – MUN:9PT - TradingView

May 12, 2026
pulisher
May 12, 2026

CCORF Downgrades Pliant Therapeutics(PLRX.US) to Hold Rating, Maintains Target Price $3 - Moomoo

May 12, 2026
pulisher
May 12, 2026

A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $2 to $3 - Moomoo

May 12, 2026
pulisher
May 12, 2026

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - markets.businessinsider.com

May 12, 2026
pulisher
May 11, 2026

Pliant Therapeutics (PLRX) Advances Clinical Trials and Pipeline Development - GuruFocus

May 11, 2026
pulisher
May 11, 2026

Pliant Therapeutics Q1 net loss narrows on lower expenses - TradingView

May 11, 2026
pulisher
May 11, 2026

Pliant Therapeutics (NASDAQ: PLRX) cuts Q1 2026 net loss to $20M - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Pliant Therapeutics (PLRX) narrows Q1 2026 loss as PLN-101095 shows early responses - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street Zen - MarketBeat

May 11, 2026
pulisher
May 09, 2026

PLRX (Pliant Therapeutics) quarterly loss narrower than feared; shares tick up as pipeline hopes support sentiment.Margin Improvement - newser.com

May 09, 2026
pulisher
May 08, 2026

The industry tailwinds powering Pliant Therapeutics (PLRX) growth (Smart Money Flows) 2026-05-08Social Buy Zones - Newser

May 08, 2026
pulisher
May 06, 2026

Pliant CEO, CFO to join RBC healthcare fireside chat on May 19 - Stock Titan

May 06, 2026
pulisher
May 04, 2026

PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

May 04, 2026
pulisher
May 04, 2026

Pliant Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView

May 04, 2026
pulisher
May 03, 2026

Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen - MarketBeat

May 03, 2026
pulisher
Apr 30, 2026

Pliant Therapeutics (PLRX) Initiates Key Clinical Trial for Canc - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Investing News Network

Apr 30, 2026
pulisher
Apr 30, 2026

Pliant Therapeutics begins trial of cancer drug combination By Investing.com - Investing.com South Africa

Apr 30, 2026
pulisher
Apr 30, 2026

Pliant Therapeutics begins trial of cancer drug combination - Investing.com

Apr 30, 2026
pulisher
Apr 30, 2026

Pliant Therapeutics Announces First Patient Dosed in - GlobeNewswire

Apr 30, 2026
pulisher
Apr 27, 2026

Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72 - MSN

Apr 27, 2026
pulisher
Apr 25, 2026

Pliant Therapeutics Inc (FRA:9PT) Stock Price & 30 Year Financial Data - GuruFocus

Apr 25, 2026
pulisher
Apr 25, 2026

Wall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Sell - MarketBeat

Apr 25, 2026
pulisher
Apr 22, 2026

Pliant Therapeutics (NASDAQ: PLRX) outlines 2026 virtual meeting, board changes and pay vote - Stock Titan

Apr 22, 2026
pulisher
Apr 22, 2026

[ARS] PLIANT THERAPEUTICS, INC. SEC Filing - Stock Titan

Apr 22, 2026
pulisher
Apr 21, 2026

Pliant Therapeutics, Inc. (PLRX) Presents at AACR Annual Meeting 2026Slideshow (NASDAQ:PLRX) 2026-04-21 - Seeking Alpha

Apr 21, 2026
pulisher
Apr 20, 2026

Primary Sclerosing Cholangitis (PSC) Market is expected to Hit - openPR.com

Apr 20, 2026
pulisher
Apr 19, 2026

Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-101095 Trials - GuruFocus

Apr 19, 2026
pulisher
Apr 19, 2026

Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-1010 - GuruFocus

Apr 19, 2026
pulisher
Apr 18, 2026

Pliant Therapeutics (PLRX) Stock: Movement Analysis (Breakout Watch) 2026-04-18Elite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026
pulisher
Apr 18, 2026

Pliant presents updated cancer trial data at AACR meeting By Investing.com - Investing.com South Africa

Apr 18, 2026
pulisher
Apr 18, 2026

Pliant Therapeutics presents updated Phase 1 data for PLN-101095 in ICI-refractory tumors - Traders Union

Apr 18, 2026
pulisher
Apr 18, 2026

Pliant presents updated cancer trial data at AACR meeting - Investing.com

Apr 18, 2026
pulisher
Apr 18, 2026

Pliant Therapeutics : Final AACR 2026 PLN10195 Yap - marketscreener.com

Apr 18, 2026
pulisher
Apr 18, 2026

Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed - TradingView

Apr 18, 2026
pulisher
Apr 18, 2026

Pliant Therapeutics Announces Presentation of Updated Data - GlobeNewswire

Apr 18, 2026

Pliant Therapeutics Inc (PLRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$29.66
price down icon 0.98%
$92.25
price up icon 0.12%
$108.87
price up icon 2.48%
$53.86
price down icon 1.17%
ONC ONC
$302.44
price down icon 2.52%
$154.89
price up icon 2.20%
大文字化:     |  ボリューム (24 時間):